These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22952347)

  • 1. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.
    Yen WC; Fischer MM; Hynes M; Wu J; Kim E; Beviglia L; Yeung VP; Song X; Kapoun AM; Lewicki J; Gurney A; Simeone DM; Hoey T
    Clin Cancer Res; 2012 Oct; 18(19):5374-86. PubMed ID: 22952347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
    Kim DH; Lee S; Kang HG; Park HW; Lee HW; Kim D; Yoem DH; Ahn JH; Ha E; You WK; Lee SH; Kim SJ; Chun KH
    BMB Rep; 2020 Nov; 53(10):533-538. PubMed ID: 32580836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
    Li JL; Sainson RC; Shi W; Leek R; Harrington LS; Preusser M; Biswas S; Turley H; Heikamp E; Hainfellner JA; Harris AL
    Cancer Res; 2007 Dec; 67(23):11244-53. PubMed ID: 18056450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
    Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
    Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delta-like ligand 4-notch blockade and tumor radiation response.
    Liu SK; Bham SA; Fokas E; Beech J; Im J; Cho S; Harris AL; Muschel RJ
    J Natl Cancer Inst; 2011 Dec; 103(23):1778-98. PubMed ID: 22010178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
    Hoey T; Yen WC; Axelrod F; Basi J; Donigian L; Dylla S; Fitch-Bruhns M; Lazetic S; Park IK; Sato A; Satyal S; Wang X; Clarke MF; Lewicki J; Gurney A
    Cell Stem Cell; 2009 Aug; 5(2):168-77. PubMed ID: 19664991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
    Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
    Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
    Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M
    Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
    Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
    PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty acid-binding protein 4, a point of convergence for angiogenic and metabolic signaling pathways in endothelial cells.
    Harjes U; Bridges E; McIntyre A; Fielding BA; Harris AL
    J Biol Chem; 2014 Aug; 289(33):23168-23176. PubMed ID: 24939870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
    Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
    Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
    MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models.
    Zhou R; Wang S; Wen H; Wang M; Wu M
    Exp Cell Res; 2019 Jul; 380(2):141-148. PubMed ID: 31034805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delta-like 4/Notch signaling promotes Apc
    Badenes M; Trindade A; Pissarra H; Lopes-da-Costa L; Duarte A
    BMC Cancer; 2017 Jan; 17(1):50. PubMed ID: 28086833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function.
    Williams CK; Li JL; Murga M; Harris AL; Tosato G
    Blood; 2006 Feb; 107(3):931-9. PubMed ID: 16219802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
    Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
    Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Molecular Mechanism of YiqiChutan Formula Regulating DLL4-Notch Signaling to Inhibit Angiogenesis in Lung Cancer.
    Li J; Han R; Li J; Zhai L; Xie X; Zhang J; Chen Y; Luo J; Wang S; Sun Z; Cao Y; Lin L; Yang Q
    Biomed Res Int; 2021; 2021():8875503. PubMed ID: 33628824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feed-forward signaling by membrane-bound ligand receptor circuit: the case of NOTCH DELTA-like 4 ligand in endothelial cells.
    Caolo V; van den Akker NM; Verbruggen S; Donners MM; Swennen G; Schulten H; Waltenberger J; Post MJ; Molin DG
    J Biol Chem; 2010 Dec; 285(52):40681-9. PubMed ID: 20959466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis.
    Djokovic D; Trindade A; Gigante J; Badenes M; Silva L; Liu R; Li X; Gong M; Krasnoperov V; Gill PS; Duarte A
    BMC Cancer; 2010 Nov; 10():641. PubMed ID: 21092311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.
    Yen WC; Fischer MM; Axelrod F; Bond C; Cain J; Cancilla B; Henner WR; Meisner R; Sato A; Shah J; Tang T; Wallace B; Wang M; Zhang C; Kapoun AM; Lewicki J; Gurney A; Hoey T
    Clin Cancer Res; 2015 May; 21(9):2084-95. PubMed ID: 25934888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.